Selected Publications

Schoeman S, Bagatell R, Cahill AM, Maris J, Mattei P, Mosse Y, Pogoriler J, Srinivasan A, Acord M. : Percutaneous Biopsy for the Diagnosis, Risk Stratification, and Molecular Profiling of Neuroblastoma: A Single Center Retrospective Study. Pediatric Blood and Cancer 71(4): e30887, 2024.

Parisio KN, Kulp T, Heil M, Li Y, Dalton K, McGrath M, Carlowicz C, Donnelly M, Bagatell R, Jubelirer T. : Yoga as a Non-Pharmacologic Therapy to Reduce Dinutuximab-Induced Pain in Patients with Neuroblastoma. Pediatric Blood and Cancer 71(4): e30845, 2024.

Kaye EC, Smith J, Zhou Y, Bagatell R, Baker JN, Cohn SL, Diller JR, Glade Bender J, Granger M, Marachelian A, Park JR, Rosenberg AR, Shusterman S, Twist CJ, Mack JW. : Factors Influencing Parents’ Choice of Palliative Treatment Goals for Children with Relapsed or Refractory Neuroblastoma: A Multi-Site Longitudinal Survey Study. Cancer December 2023.

Bagatell R, DuBois SG, Naranjo A, Belle J, Goldsmith KC, Park JR, Irwin MS. : Children’s Oncology Group’s 2023 Blueprint for Research: Neuroblastoma. Pediatric Blood and Cancer Page: e30572, July 2023.

Bacchus MK, Anderson DS, Berko ER, States LJ, Bagatell R, Hopkins S, Batra V: Neuroblastic Tumor Recurrence Associated with Opsoclonus Myoclonus Ataxia Syndrome Relapse a Decade after Initial Resection and Treatment. J Pediatr Hematol Oncol. 45(3): 152-154, January 2023 Notes: Accepted

Streby K, Parisi M, Shulkin B, LaBarre B, Bagatell R, Diller L, Grupp SA, Matthay KK, Voss S, Yu AL, London W, Park JR, Yanik G, Naranjo A.: Impact of Diagnostic and End-Induction Curie Scores with Tandem Autologous Transplants for Metastatic High-Risk Neuroblastoma: A Report from the Children’s Oncology Group. Pediatric Blood and Cancer 70(8): e30418, 2023.

Pinto N, Naranjo A, Ding X, Zhang FF, Hibbitts E, Kennedy R, Pfau R, Tibbetts R, Wong-Michalak S, Craig DW, Manojlovic Z, Hogarty MD, Kreissman S, Bagatell R, Irwin MS, Park JR, Asgharzadeh S: Impact of Genomic and Clinical Factors on Outcome of Children>18 months of Age with INSS Stage 3 Neuroblastoma with Unfavorable Histology without MYCN Amplification. Clinical Cancer Research 29(8): 1546-1556, 2023.

Naranjo A, Bagatell R, Greengard EG, DuBois SG.: ANBL1531: The Children’s Oncology Group (COG) Experience Using a Bayesian Approach. Chapter 2. Case Studies in Innovative Clinical Trials, Broglio K, Ed Page: 19-27, 2023.

Hill-Kayser CE, Li Y, Kurtz G, Mattei P, Balis F, Lustig RA, LaRiviere M, MacFarland S, Batra V, Mosse Y, Maris JM, Balamuth N, Bagatell R. : Survival and Local Recurrence Risk in Patients with High-Risk Neuroblastoma Treated with Proton Therapy over a 10 Year Interval. Int J Radiat Oncol Biol Phys 117(2S): e516-e517, 2023.

Erbe AK, Diccianni MB, Mody R, Naranjo A, Zhang FF, Birstler J, Kim K, Feils AS, Hung J-T, London WB, Shulkin BL, Matthew V, Parisi MT, Servaes S, Asgharzadeh S, Maris JM, Park JR, Yu AL, Sondel PM, Bagatell R. : KIR/KIR-Ligand Genotypes and Clinical Outcomes Following Chemo-immunotherapy in Patients with Relapsed or Refractory Neuroblastoma: A Report from the Children’s Oncology Group. Journal of Immunotherapy of Cancer 11(2): e006530, 2023.